Literature DB >> 8457467

Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors.

K V Watson1, N Key.   

Abstract

Essential thrombocythaemia (ET) is a myeloproliferative disorder characterized by absolute thrombocytosis and increased incidence of thrombosis and haemorrhage. We report higher morbidity in patients with ET due to arterial ischaemic complications when cardiovascular risk factors are present. In this retrospective analysis of 46 patients, arterial complications occurred in 20/46 patients (43.4%); patients with cardiovascular risk factors, especially cigarette smoking, had more than twice as many arterial complications than patients without risk factors (62.5% v 22.7%, P < 0.05). Neither age, gender nor degree of thrombocytosis were linked to the number of complications. In contrast, we observed no association between cardiovascular risk factors and venous thrombosis or haemorrhagic complications of ET.

Entities:  

Mesh:

Year:  1993        PMID: 8457467     DOI: 10.1111/j.1365-2141.1993.tb08272.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

Review 1.  Primary thrombocythemia: diagnosis, clinical manifestations and management.

Authors:  P J van Genderen; J J Michiels
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

2.  Cardiac surgery in a patient with essential thrombocythemia: a case report.

Authors:  B E Schölzel; H Endeman; W Dewilde; A Yilmaz; O de Weerdt; J M Ten Berg
Journal:  Neth Heart J       Date:  2010-08       Impact factor: 2.380

Review 3.  Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature.

Authors:  S L Senno; L Pechet
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

Review 4.  Polycythaemia vera and essential thrombocythaemia in the elderly.

Authors:  P J van Genderen; M M Troost
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

5.  Cardiovascular Manifestations of Myeloproliferative Disorders: A Review of the Literature.

Authors:  Muhammad Wasif Saif; Umer Khan; Bernard R Greenberg
Journal:  Hosp Physician       Date:  1999-07

6.  Cardiac Complications of Myeloproliferative Disorders.

Authors:  Muhammad Wasif Saif; Umer Khan; Bernard R Greenberg
Journal:  Resid Staff Physician       Date:  2001-07

7.  Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera.

Authors:  Marina Karakantza; Nikolaos C Giannakoulas; Panagiotis Zikos; George Sakellaropoulos; Alexandra Kouraklis; Anthi Aktypi; Ioannis C Metallinos; Eleni Theodori; Nicholas C Zoumbos; Alice Maniatis
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

8.  Aortic thrombus in a patient with myeloproliferative thrombocytosis, successfully treated by pharmaceutical therapy: a case report.

Authors:  Hidesuke Yamamoto; Haruaki Nishimaki; Norikazu Imai; Masakazu Nitta; Osami Daimaru
Journal:  J Med Case Rep       Date:  2010-07-21

9.  Postpartal recurrent non-ST elevation myocardial infarction in essential thrombocythaemia: case report and review of the literature.

Authors:  Spyridon Arampatzis; Ioannis Stefanidis; Vassilios Lakiopoulos; Luigi Raio; Daniel Surbek; Markus G Mohaupt
Journal:  Thromb J       Date:  2010-06-17

Review 10.  Essential thrombocythemia.

Authors:  Jean B Brière
Journal:  Orphanet J Rare Dis       Date:  2007-01-08       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.